Categories AlphaGraphs, Earnings, Health Care
Infographic: Highlights of Abiomed (ABMD) Q4 2020 earnings report
Medical device maker Abiomed, Inc. (NASDAQ: ABMD) reported a decline in fourth quarter earnings even as revenues remained flat. The company withheld its full-year guidance, citing the uncertainties caused by the Covid-19 outbreak. Following the announcement, the stock gained sharply in early trading on Thursday.
Net income dropped 57% annually to $31.8 million or $0.70 per share and came in below analysts’ estimates. At $206.7 million, revenue was unchanged year-over-year.
In the US, revenues of Impella dropped 3%, while revenues of the flagship product rose 12% in the international market. Abiomed’s stock dropped 31% in the past twelve months. After slipping to a multi-year low last month, the stock is regaining strength.
Most Popular
Novavax (NVAX) stock tumbles despite beating bottom line estimates in Q2
After Novavax (NASDAQ: NVAX) reported its progress on developing the COVID-19 vaccine at the end of February, the shares of the company started trading in double-digits after a long time.
During tough times, Tilray (TLRY) looks overseas to achieve growth targets
Cannabis was recognized as an essential business in several markets when the shutdown came into effect, including Canada and some US states, at a time when its legalization is getting
Eastman Kodak (KODK) swings to a loss in Q2 2020; revenue drops 31%
Eastman Kodak (NYSE: KODK) reported a loss of $5 million on revenue of $213 million in the second quarter of 2020. The company earned $201 million in the prior-year quarter.